Results 11 to 20 of about 408 (149)

Immunocytokines in cancer: a safety perspective

Frontiers in Immunology
Immunocytokines (ICs) are engineered biologics comprising a fusion of cytokines to antibodies, designed to deliver targeted cytokines to diseased tissues and mitigate the severe safety challenges associated with systemic cytokine therapy.
Kushal Prajapati, Catherine Betts, Richard Stebbings   +2 more
doaj   +3 more sources

The present and future of immunocytokines for cancer treatment

Cellular and Molecular Life Sciences, 2022
AbstractMonoclonal antibody (mAb) therapy has successfully been introduced as treatment of several lymphomas and leukemias. However, solid tumors reduce the efficacy of mAb therapy because of an immune-suppressive tumor micro-environment (TME), which hampers activation of effector immune cells.
Dennis Y. Gout, Lotte S. Groen, Marjolein van Egmond   +2 more
openaire   +3 more sources

Anti-CD70 immunocytokines for exploitation of interferon-γ-induced RIP1-dependent necrosis in renal cell carcinoma. [PDF]

PLoS ONE, 2013
Metastatic renal cell carcinoma (RCC) is an incurable disease in clear need of new therapeutic interventions. In early-phase clinical trials, the cytokine IFN-γ showed promise as a biotherapeutic for advanced RCC, but subsequent trials were less ...
Peirong Chen, Shoko Nogusa, Roshan J Thapa, Calvin Shaller, Heidi Simmons, Suraj Peri, Gregory P Adams, Siddharth Balachandran   +7 more
doaj   +2 more sources

Immunocytokines in cancer treatment: A systematic review [PDF]

Cancer Treatment Reviews
Immunocytokines are an emerging class of antibody-cytokine fusion proteins combining the specificity of monoclonal antibodies with the potent immunostimulatory effects of cytokines, potentially enhancing the anti-tumor immune response while reducing systemic toxicity.We conducted a systematic review following the PRISMA guidelines.
Agliardi, Stefano, Veronese, Chiara, Panzeri, Ferdinando, Palazzini, Simonetta, Guarnieri, Greta, Loiacono, Stefano, Martinelli, Vanessa, Potenza, Anna Maria, Sbraga, Emanuele, Rissotto, Eleonora, Inglese, Elvira, Tosi, Federica, Villa, Federica, Patelli, Giorgio, Monti, Letizia, Pani, Arianna, Danesi, Romano, Fornasari, Diego, Siena, Salvatore, Sartore-Bianchi, Andrea   +19 more
openaire   +3 more sources

Cotargeting TREM2 and IL2 pathways triggers multipronged anticancer immunity

Molecular Oncology
Triggering receptor expressed on myeloid cells 2 (TREM2) has emerged as a key immunosuppressive target on tumour‐associated macrophages (TAMs), where it coordinates protumorigenic and anti‐inflammatory functions within the tumour microenvironment (TME ...
Isaure Vanmeerbeek, Jenny Sprooten, Abhishek D. Garg   +2 more
doaj   +2 more sources

Current and Potential Uses of Immunocytokines as Cancer Immunotherapy

Antibodies, 2012
Immunocytokines (ICs) are a class of molecules created by linking tumor-reactive monoclonal antibodies to cytokines that are able to activate immune cells.
Paul M. Sondel, Stephen D. Gillies
doaj   +2 more sources

Efficacy of Anti-Cancer Immune Responses Elicited Using Tumor-Targeted IL-2 Cytokine and Its Derivatives in Combined Preclinical Therapies [PDF]

Vaccines
Effective cancer therapies must address the tumor microenvironment (TME), a complex network of tumor cells and stromal components, including endothelial, immune, and mesenchymal cells. Durable outcomes require targeting both tumor cells and the TME while
Sahar Balkhi, Giorgia Bilato, Andrea De Lerma Barbaro, Paola Orecchia, Alessandro Poggi, Lorenzo Mortara   +5 more
doaj   +2 more sources

CLEC12A-directed immunocytokine with target cell–restricted IL-15 activity for treatment of acute myeloid leukemia [PDF]

Frontiers in Immunology
Despite recent advancements, acute myeloid leukemia (AML) remains a therapeutic challenge. While monoclonal antibodies (mAbs) leveraging natural killer (NK) cells through antibody-dependent cellular cytotoxicity show great potential, none have gained ...
Boris Klimovich, Boris Klimovich, Leonard Anton, Jinwon Jung, Yangmi Lim, Bora Lee, Jonghwa Won, Latifa Zekri, Latifa Zekri, Anna Chashchina, Anna Chashchina, Martin Pflügler, Jonas S. Heitmann, Jonas S. Heitmann, Gundram Jung, Helmut R. Salih, Helmut R. Salih   +16 more
doaj   +2 more sources

Beyond checkpoint inhibition – Immunotherapeutical strategies in combination with radiation

Clinical and Translational Radiation Oncology, 2017
The revival of cancer immunotherapy has taken place with the clinical success of immune checkpoint inhibition. However, the spectrum of immunotherapeutic approaches is much broader encompassing T cell engaging strategies, tumour-specific vaccination ...
F. Eckert, U.S. Gaipl, G. Niedermann, M. Hettich, K. Schilbach, S.M. Huber, D. Zips   +6 more
doaj   +2 more sources

Immunocytokines with activity-on-demand by combination with small molecule inhibitors

EMBO Molecular Medicine
Dose-limiting systemic toxicity constitutes a major impediment to the application of cytokines in cancer therapy. To enhance the therapeutic index, tumor-directed antibody-cytokine fusion proteins, i.e., immunocytokines, are developed for targeting ...
Dafne Müller
doaj   +2 more sources